Manufacturing & Supply Chain
M&A & PMI.
We assist buyers, sellers, and investors in the life sciences sector with regulatory due diligence, QMS integration, and post-merger compliance management.
What compliance risks arise in life sciences M&A?
Mergers and acquisitions in the life sciences sector present specific regulatory challenges:
- Regulatory gaps at the target are not fully identified during due diligence
- The importance of QMS integration following an acquisition is often underestimated—two different systems clash
- Approvals, certificates, and licenses must be transferred to the new holder
- Cultural differences in quality and compliance practices significantly delay integration
Did you conduct a full regulatory due diligence during your most recent M&A process?
Our services.
We bring regulatory and quality expertise to every stage of the M&A process.
Regulatory Due Diligence
Assessment of the target company’s regulatory risks: approval status, QMS quality, open communication with regulatory authorities, CAPA backlogs, and ongoing inspection findings. Structured red flag report to support investment decisions.
QMS Gap Analysis & Integration Strategy
Assessment of both companies’ QMS systems: compatibility, standards compliance, and integration needs. Development of a realistic QMS integration strategy with milestones and assigned responsibilities.
Post-Merger Compliance Management
Support for regulatory integration: marketing authorization transfers, communication with notified bodies, and EUDAMED updates. Change control management for all regulatory changes during the integration process.
Cultural Integration & Quality Culture
Supporting the integration of a quality culture: aligning quality policies, training programs, and quality values. Identifying and resolving cultural compliance issues.
Frequently Asked Questions About M&A and PMI in the Life Sciences Industry.
What is regulatory due diligence in the life sciences?
Regulatory due diligence is the systematic assessment of a target company’s regulatory status, approvals, QMS, and compliance history prior to an acquisition. Objective: To identify risks and hidden liabilities that could affect the purchase price or integration costs.
What are common regulatory red flags in life sciences M&A?
Outstanding FDA warning letters, pending major findings from GMP inspections, unresolved communications with regulatory authorities, ongoing product recalls, incomplete or outdated regulatory filings, a massive CAPA backlog, or GLP compliance issues.
How are licenses transferred when a company is sold?
Marketing authorization transfers require formal variation applications to be submitted to the relevant authorities: within the EU, the procedures vary depending on the type of authorization; in the U.S., this involves an “Ownership Transfer” with the FDA. ENTOURAGE plans and supports these processes in parallel with operational integration.
How long does it take to fully integrate a QMS following an acquisition?
Typically 12 to 36 months—depending on the size and complexity of the companies involved, the degree of differences in their QMS, and regulatory requirements. Early planning and clear governance are critical to the success of the integration.
Related topics.
Submit a project inquiry.
Please briefly describe your current challenge. An expert from our team will contact you shortly.